SRX246: Completed Phase II enrollment

Azevan completed enrollment of 96 patients in a double-blind, placebo-controlled, dose-escalation, U.S. Phase II trial evaluating twice-daily oral SRX246 for 8 weeks. Patients receive 120 mg SRX246 fo...